# A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

> **NCT02467361** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 104 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** BBI608
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02467361
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2021-01-29
- **Final completion:** 2021-01-29
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02467361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02467361, "A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02467361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*